3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Melanoma
42
Carcinoma, Non-Small-Cell Lung
13
Carcinoma, Renal Cell
10
Colorectal Neoplasms
9
Neoplasm Metastasis
8
Ovarian Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Neoplasms
6
Breast Neoplasms
6
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Lung Neoplasms
5
Head and Neck Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Ovarian Epithelial
4
Uveal Melanoma
3
Esophageal Neoplasms
3
Brain Neoplasms
3
Triple Negative Breast Neoplasms
2
Skin Neoplasms
2
Sezary Syndrome
2
Sarcoma
2
Prostatic Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Mycosis Fungoides
2
Melanoma, Cutaneous Malignant
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Interventions
pembrolizumab
3
Paclitaxel
2
relatlimab
1
nintedanib
1
lifileucel
1
dabrafenib
1
Vitamin D
1
Temozolomide
1
Surveys and Questionnaires
1
Opdualag
1
Nivolumab
1
Microarray Analysis
1
Ipilimumab
1
Genetic Testing
1
Gene Expression Profiling
1
Eye Movement Desensitization Reprocessing
1
Electrochemotherapy
1
Dacarbazine
1
Cholecalciferol
1
Carboplatin
1
Biopsy
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Melanoma, Cutaneous Malignant
×
Paclitaxel
×
Dermatologic
×
Clear all
NCT06743126
2026-04-21
SUPRAME
Immatics US, Inc.
Phase 3
Recruiting
360 enrolled
NCT02308553
2020-10-14
NIPAWILMA
University Hospital, Essen
Phase 1/2
Completed
33 enrolled